Attempts to discover new drugs for genetically complex brain disorders have proven extremely difficult. Insufficient knowledge of the underlying biological mechanisms represents a critical challenge impacting the drug discovery process. This challenge is driving the need for innovative HTS methods that can elucidate the complex cellular communication, such as in primary mouse neurons and human disease models, in the early stages of drug discovery.

At Systasy, we address this need by delivering unmatched mode-of-action insights through highly multiplexed phenogenomic pathway profiling technologies for target selection, lead discovery, and safety profiling.